BioLife Solutions (NASDAQ:BLFS) Rating Lowered to “Sell” at Wall Street Zen

BioLife Solutions (NASDAQ:BLFS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $31.17.

BioLife Solutions Stock Up 0.0%

BLFS stock opened at $22.10 on Wednesday. BioLife Solutions has a 1 year low of $18.70 and a 1 year high of $29.55. The company has a fifty day simple moving average of $23.27 and a 200 day simple moving average of $25.24. The firm has a market cap of $1.05 billion, a PE ratio of -20.85 and a beta of 2.01. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $23.94 million during the quarter, compared to analysts’ expectations of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. Sell-side analysts anticipate that BioLife Solutions will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Sarah Aebersold sold 5,771 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the sale, the insider now owns 80,094 shares of the company’s stock, valued at approximately $1,814,930.04. This trade represents a 6.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Todd Berard sold 1,577 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,425.00. Following the sale, the chief marketing officer now directly owns 104,961 shares of the company’s stock, valued at approximately $2,624,025. The trade was a 1.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,696 shares of company stock valued at $1,665,094 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the business. Proficio Capital Partners LLC acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at $638,000. Alliancebernstein L.P. increased its position in BioLife Solutions by 11.9% in the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider’s stock valued at $970,000 after acquiring an additional 3,967 shares in the last quarter. Envestnet Asset Management Inc. increased its position in BioLife Solutions by 18.6% in the 4th quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider’s stock valued at $5,158,000 after acquiring an additional 31,167 shares in the last quarter. Victory Capital Management Inc. increased its position in BioLife Solutions by 422.2% in the 4th quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider’s stock valued at $5,684,000 after acquiring an additional 177,028 shares in the last quarter. Finally, D.A. Davidson & CO. increased its position in BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after acquiring an additional 519 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.